Lipocine to Present at A.G.P.'s Annual Healthcare Company Showcase
Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on oral drug delivery technology, has announced its participation in A.G.P.'s Annual Healthcare Company Showcase. The virtual presentation is scheduled for Wednesday, May 21, 2025, at 4:00 pm ET. Investors can access the presentation and its replay through the company's website's Investors section. The company's presentation will highlight its proprietary technology platform designed to enhance therapeutics through effective oral delivery solutions.
Lipocine Inc. (NASDAQ: LPCN), un'azienda biofarmaceutica specializzata nella tecnologia per la somministrazione orale di farmaci, ha annunciato la sua partecipazione al Annual Healthcare Company Showcase di A.G.P.. La presentazione virtuale è prevista per mercoledì 21 maggio 2025, alle 16:00 ET. Gli investitori potranno accedere alla presentazione e alla sua registrazione attraverso la sezione Investitori del sito web dell'azienda. Durante la presentazione, l'azienda illustrerà la sua piattaforma tecnologica proprietaria, progettata per migliorare i trattamenti terapeutici tramite soluzioni efficaci per la somministrazione orale.
Lipocine Inc. (NASDAQ: LPCN), una compañía biofarmacéutica centrada en la tecnología de administración oral de medicamentos, ha anunciado su participación en el Annual Healthcare Company Showcase de A.G.P.. La presentación virtual está programada para el miércoles 21 de mayo de 2025 a las 4:00 pm ET. Los inversores podrán acceder a la presentación y su repetición a través de la sección de Inversores en el sitio web de la compañía. La presentación destacará la plataforma tecnológica propia de la empresa, diseñada para mejorar las terapias mediante soluciones efectivas de administración oral.
Lipocine Inc. (NASDAQ: LPCN)는 경구 약물 전달 기술에 중점을 둔 생명공학 회사로, A.G.P. 연례 헬스케어 기업 쇼케이스에 참여할 예정임을 발표했습니다. 가상 발표는 2025년 5월 21일 수요일 오후 4시(동부시간)에 진행됩니다. 투자자들은 회사 웹사이트의 투자자 섹션을 통해 발표 및 재생 영상을 시청할 수 있습니다. 회사 발표에서는 효과적인 경구 전달 솔루션을 통해 치료제를 향상시키기 위해 설계된 독자적인 기술 플랫폼을 소개할 예정입니다.
Lipocine Inc. (NASDAQ : LPCN), une société biopharmaceutique spécialisée dans la technologie d'administration orale de médicaments, a annoncé sa participation au Annual Healthcare Company Showcase d'A.G.P.. La présentation virtuelle est prévue pour le mercredi 21 mai 2025 à 16h00 ET. Les investisseurs pourront accéder à la présentation et à sa rediffusion via la section Investisseurs du site web de la société. La présentation mettra en avant la plateforme technologique propriétaire de l'entreprise, conçue pour améliorer les traitements grâce à des solutions efficaces d'administration orale.
Lipocine Inc. (NASDAQ: LPCN), ein biopharmazeutisches Unternehmen mit Fokus auf orale Arzneimittelabgabetechnologie, hat seine Teilnahme an der A.G.P. Annual Healthcare Company Showcase angekündigt. Die virtuelle Präsentation ist für Mittwoch, den 21. Mai 2025, um 16:00 Uhr ET geplant. Investoren können die Präsentation sowie die Aufzeichnung über den Investor-Bereich der Unternehmenswebsite abrufen. Die Präsentation wird die firmeneigene Technologieplattform hervorheben, die darauf ausgelegt ist, Therapien durch effektive orale Abgabelösungen zu verbessern.
- None.
- None.
Presentation Details
Time: | 4:00 pm ET |
Date: | Wednesday, May 21, 2025 |
Webcast Link: | https://us02web.zoom.us/webinar/register/WN_jB1HgKLvQFmUfC6VBT11mw |
The webcast and replay of the presentation will be accessible in the Investors section of Lipocine's website.
About Lipocine
Lipocine is a biopharmaceutical company leveraging its proprietary technology platform to enable effective oral delivery of therapeutics. Lipocine has drug candidates in development as well as drug candidates for which we are exploring partnerships. Our drug candidates represent enablement of differentiated, patient friendly oral delivery options for favorable benefit to risk profile which target large addressable markets with significant unmet medical needs.
Lipocine's clinical development candidates include: LPCN 1154, oral brexanolone, for the potential treatment of postpartum depression, LPCN 2101 for the potential treatment of epilepsy, LPCN 2203 an oral candidate targeted for the management of essential tremor, LPCN 2401 an oral proprietary anabolic androgen receptor agonist, as an adjunct therapy to incretin mimetics, as an aid for improved body composition in obesity management and LPCN 1148, a novel androgen receptor agonist prodrug for oral administration targeted for the management of symptoms associated with liver cirrhosis. Lipocine is exploring partnering opportunities for LPCN 1107, our candidate for prevention of preterm birth, LPCN 1154, for rapid relief of postpartum depression, LPCN 2401 for obesity management, LPCN 1148, for the management of decompensated cirrhosis, and LPCN 1144, our candidate for treatment of metabolic dysfunction-associated steatohepatitis (MASH). TLANDO, a novel oral prodrug of testosterone containing testosterone undecanoate developed by Lipocine, is approved by the FDA for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism, in adult males. For more information, please visit www.lipocine.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/lipocine-to-present-at-agps-annual-healthcare-company-showcase-302454609.html
SOURCE Lipocine Inc.
FAQ
When is Lipocine (LPCN) presenting at A.G.P.'s Healthcare Company Showcase 2025?
How can investors access Lipocine's presentation at the A.G.P. Healthcare Showcase?
What is Lipocine's (LPCN) main business focus?
Is the A.G.P. Healthcare Company Showcase 2025 an in-person or virtual event?
